Vaishali Sanchorawala, MD
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MBBS, Seth G.S. Medical College

Pronouns: she/her/hers



72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)

Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.

Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Boston University School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.

Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.

Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.

She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.

Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.

Associate Director
Boston University School of Medicine
Amyloidosis Center


Member
Boston University
BU-BMC Cancer Center


Director
Boston Medical Center
Stem Cell Transplantation Program
Hematology & Medical Oncology

Secretary
International Society of Amyloidosis


Executive committee
Amyloidosis Research Consortium


Associate Editor
Amyloid: The Journal of Protein Folding disorders



2015 Research mentor award
2015 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2011 Research Mentoring Award nomination
2011 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2007-2009 Robert Dawson Evans Clinician Award
2000 IBMTR/ABMTR: Mortimer M. Bortin Award for best abstract


A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2021 (PI)
Millennium Pharmaceuticals, Inc.


A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2021 (PI)
Celgene Corporation


Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2020 (Subcontract Co-PI)
The Brigham and Women's Hospital, Inc. NIH NHLBI
5R01HL130563-04

A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium


Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (Subcontract PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc


A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis
05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited


An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.


A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of
01/06/2016 - 01/05/2019 (Subcontract Co-PI)
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn


A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 PLus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagno
12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.


Phase II trial of induction therapy with Bortezomib and Dexamethasone followed by high-dose melphalan and stem cell transplantation in patients with AL amyloidosis
04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.


Showing 10 of 14 results. Show All Results

DFCI 19-291: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone…
12/23/2019 - 12/22/2022 (PI)
Dana Farber Millennium Pharmaceu

Oncopeptides: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL…
11/21/2019 - 11/20/2022 (PI)
Oncopeptides AB

54767414MMY3019 DARA
04/15/2019 - 04/15/2022 (PI)
Janssen Scientific Affairs LLC

DARA/JANSSEN PI Initiated
03/28/2017 - 03/28/2021 (PI)
Janssen Scientific Affairs LLC

54767414AMY3001
11/17/2017 - 11/17/2020 (PI)
Janssen Research and Development, LLC

NEOD001-CL002
09/24/2015 - 09/30/2019 (PI)
Prothena Therapeutics Limited

PRONTO - Protocol NEOD001-201
05/13/2016 - 03/31/2019 (PI)
Prothena Therapeutics Limited

Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …
05/11/2015 - 03/31/2019 (PI)
Karmanos Cancer Center

Secondary Analysis of Amyloid Repository Data
09/15/2015 - 09/14/2017 (PI)
Prothena Therapeutics Limited


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, Liedtke M, Jaccard A, Wechalekar AD, Comenzo R, Sanchorawala V, Royer B, Rosenzweig M, Valent J, Schönland S, Fonseca R, Wong S, Kapoor P. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021 Jan 11; 11(1):10. PMID: 33431806
     
  2. Palladini G, Schönland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, Milani P, Ando Y, Westermark P, Dispenzieri A, Merlini G. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021 Jan 07; 1-2. PMID: 33410355
     
  3. Lovley A, Raymond K, Guthrie SD, Pollock M, Sanchorawala V, White MK. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being. J Patient Rep Outcomes. 2021 Jan 07; 5(1):3. PMID: 33411323
     
  4. Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020 11 10; 10(11):118.View Related Profiles. PMID: 33173025
     
  5. Hughes DM, Staron A, Sanchorawala V. A pharmacist's review of the treatment of systemic light chain amyloidosis. J Oncol Pharm Pract. 2021 Jan; 27(1):187-198. PMID: 33028132
     
  6. Law ST, Jafarzadeh SR, Govender P, Sun X, Sanchorawala V, Kissin EY. Comparison of Ultrasound Features of Major Salivary Glands in Sarcoidosis, Amyloidosis, and Sjögren's Syndrome. Arthritis Care Res (Hoboken). 2020 10; 72(10):1466-1473.View Related Profiles. PMID: 31309727
     
  7. Hoffman JE, Dempsey NG, Sanchorawala V. Systemic Amyloidosis Caused by Monoclonal Immunoglobulins: Soft Tissue and Vascular Involvement. Hematol Oncol Clin North Am. 2020 Dec; 34(6):1099-1113. PMID: 33099427
     
  8. Sarosiek S, Zheng L, Sloan JM, Quillen K, Brauneis D, Sanchorawala V. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer J. 2020 09 01; 10(8):88.View Related Profiles. PMID: 32873776
     
  9. Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2020 Jul 31.View Related Profiles. PMID: 32737434
     
  10. Schulman A, Connors LH, Weinberg J, Mendelson LM, Joshi T, Shelton AC, Sanchorawala V. Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. Eur J Haematol. 2020 Oct; 105(4):495-501.View Related Profiles. PMID: 32564450; DOI: 10.1111/ejh.13472;
     
Showing 10 of 190 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 190 publications over 24 distinct years, with a maximum of 18 publications in 2020

YearPublications
19941
19982
19991
20014
20021
20035
20046
20055
200611
20076
20082
20097
201012
201112
201210
20135
201410
201510
201611
201715
201817
201916
202018
20213

Facebook Live

18th Annual Woman of the Year Awards Gala Postponed Until Next Spring: April 30

INDIA New England News 9/3/2020

Daratumumab Safe And Effective Option For Treating Light Chain (AL) Amyloidosis

Medical Dialogues 2/4/2020
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Amyloidosis [C18.452.845.500]
Stem cell transplantation
Clinical research
QoL

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

72 East Concord Street, K-503
Boston MA 02118
Google Map

617.358.4750
Download vCard

Sanchorawala's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (364) concept(s)
_
Media Mentions
_
Co-Authors
See all (46) people
_
Similar People
See all (60) people
_
Same Department
Search Department